New atypical antipsychotic for schizophrenia has ‘negligible’ weight effect

Go red for women: young woman jogging outdoors
A new atypical antipsychotic medication that provides a sustained improvement of the symptoms of schizophrenia with negligible effect on patients’ metabolic parameters has been welcomed by Australian experts. Professor David Castle from Melbourne says the availability of Latuda (lurasidone HCl) on the PBS (from 1 November 2015) for the treatment of schizophrenia in adults has

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacists need to prepare consumers on PBS delisting: Demarte
Next Industry urged to coordinate on health insurance review: Sclavos